New Course ‘Skills for Patient Oriented Research’ Added to ImPORTND Training Platform
The third and final module of our patient-oriented research training platform, ImPORTND, is now available! ‘Skills for Patient-Oriented Research’ teaches specific skills to help with patient-oriented research (POR), including how to develop an effective patient engagement plan, share and listen to patient stories, and evaluate project engagement.
Register for 'Skills for Patient-Oriented Research' here!
ImPORTND Platform
The ImPORTND platform offers online, self-directed, free neuromuscular-specific training on how to conduct research that is informed by, and most meaningful to individuals living with neuromuscular diseases and are designed for all members of the study team: including researchers, lab staff, and patient- and family partners. ImPORTND consists of three modules: Readiness for Patient-Oriented Reseach, Inclusion/Diversity/Equity/Accessibility (IDEA), and Skills for Patient-Oriented Research. All are available in English (imPORTND) and French (inFORMERMN). Learn more about the development of these training modules on the NMD4C website.
Free Training and Support Services
Taking the first steps towards establishing a patient-oriented research strategy can be the most challenging, which is why we are partnering with Muscular Dystrophy Canada (MDC) to offer free training and support services for both research teams and patients to empower all members of the research team to conduct research that is informed by, and most meaningful to individuals living with neuromuscular diseases.
We are working with MDC to connect research teams with trained patient partners whose experiences and research interests align with the proposed area of research, and support to compensate patient-partners for their involvement.
Take the Training
Begin the training here!
If you have any questions about the training, please contact network manager Erin Beattie at .
Read next...
Hope on the Horizon: Trials, Treatments and Therapies for DMD, DM1 & MG
Nov 25-28, 2025 | Join us at Hope on the Horizon to learn more about the treatment and clinical trial landscape for Duchenne Muscular Dystrophy, Myotonic Dystrophy Type 1 and Myasthenia Gravis from key experts in the field!
2026 Awards Now Open for Nominations!
We’re proud to recognize outstanding achievements across the neuromuscular research community with our Three awards: Publication of the Year, Early Career Biomedical/Clinical Researchers of the Year.
A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada. Patient Support Program opens for enrollment on October 10, 2025.